ParkinsonCanadaV1, PascalFrancis, Curation, bibRecord, 000243

Burden of parkinsonism: A population-based study

Identifieur interne : 000243 ( PascalFrancis/Curation ); précédent : 000242; suivant : 000244

Burden of parkinsonism: A population-based study

Auteurs : Mark Guttman [Canada] ; Pamela M. Slaughter [Canada] ; Marc-Erick Theriault [Canada] ; Donald P. Deboer [Canada] ; C. David Naylor [Canada]

Source :

Movement disorders [ 0885-3185 ] ; 2003.

RBID : Pascal:03-0238018

Descripteurs français

Pascal (Inist)
- Parkinsonisme, Analyse coût, Coût, Etude cohorte, Hospitalisation, Canada, Epidémiologie, Prévalence, Economie santé, Homme.
Wicri :
- geographic : Canada.
- topic : Hospitalisation, Homme.

English descriptors

KwdEn :
- Canada, Cohort study, Cost analysis, Costs, Epidemiology, Health economy, Hospitalization, Human, Parkinsonism, Prevalence.

Abstract

Parkinson's disease (PD) is associated with a significant burden of illness and cost to society, which has been difficult to quantify. Our objective was to use linked administrative databases from the population of Ontario, Canada, to assess the prevalence of parkinsonism, physician- and drug-related costs, and hospital utilization for parkinsonian patients compared with age/sex matched controls. An inception cohort of parkinsonian cases from 1993/ 1994 was age and sex matched (1:2) to controls and followed for 6 years. Patients were identified by the diagnostic code for PD, the use of specific PD drugs, or a combination. The parkinsonian case cohort (15,304) was matched to (30,608) controls that did not have parkinsonism. The age-adjusted prevalence rates were 3.63 for men and for 3.24 women per 1,000 (increased by 5.4% for men and 9.8% for women). Physician costs were 1.4 times more, there were 1.44 times more hospital admissions, admissions were on average 1.19 times longer, and drug costs were 3.0 times more for parkinsonian cases. We conclude that the substantially higher physician and drug costs as well as hospitalization rates compared with controls clearly suggest that parkinsonism is associated with large direct costs to society.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 18`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Burden of parkinsonism: A population-based study`
A11	`01`	`1`		`@1 GUTTMAN (Mark)`
A11	`02`	`1`		`@1 SLAUGHTER (Pamela M.)`
A11	`03`	`1`		`@1 THERIAULT (Marc-Erick)`
A11	`04`	`1`		`@1 DEBOER (Donald P.)`
A11	`05`	`1`		`@1 NAYLOR (C. David)`
A14	`01`			`@1 Division of Neurology, Department of Medicine, University of Toronto @2 Toronto, Ontario @3 CAN @Z 1 aut.`
A14	`02`			`@1 Institute for Clinical Evaluative Sciences (ICES) @2 Toronto, Ontario @3 CAN @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut.`
A14	`03`			`@1 Dean's Office, Faculty of Medicine, University of Toronto @2 Toronto, Ontario @3 CAN @Z 5 aut.`
A20				`@1 313-319`
A21				`@1 2003`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000109859510100`
A44				`@0 0000 @1 © 2003 INIST-CNRS. All rights reserved.`
A45				`@0 26 ref.`
A47	`01`	`1`		`@0 03-0238018`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Parkinson's disease (PD) is associated with a significant burden of illness and cost to society, which has been difficult to quantify. Our objective was to use linked administrative databases from the population of Ontario, Canada, to assess the prevalence of parkinsonism, physician- and drug-related costs, and hospital utilization for parkinsonian patients compared with age/sex matched controls. An inception cohort of parkinsonian cases from 1993/ 1994 was age and sex matched (1:2) to controls and followed for 6 years. Patients were identified by the diagnostic code for PD, the use of specific PD drugs, or a combination. The parkinsonian case cohort (15,304) was matched to (30,608) controls that did not have parkinsonism. The age-adjusted prevalence rates were 3.63 for men and for 3.24 women per 1,000 (increased by 5.4% for men and 9.8% for women). Physician costs were 1.4 times more, there were 1.44 times more hospital admissions, admissions were on average 1.19 times longer, and drug costs were 3.0 times more for parkinsonian cases. We conclude that the substantially higher physician and drug costs as well as hospitalization rates compared with controls clearly suggest that parkinsonism is associated with large direct costs to society.
C02	`01`	`X`		`@0 002B17A01`
C03	`01`	`X`	`FRE`	`@0 Parkinsonisme @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinsonism @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson síndrome @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Analyse coût @5 04`
C03	`02`	`X`	`ENG`	`@0 Cost analysis @5 04`
C03	`02`	`X`	`SPA`	`@0 Análisis costo @5 04`
C03	`03`	`X`	`FRE`	`@0 Coût @5 05`
C03	`03`	`X`	`ENG`	`@0 Costs @5 05`
C03	`03`	`X`	`SPA`	`@0 Costo @5 05`
C03	`04`	`X`	`FRE`	`@0 Etude cohorte @5 07`
C03	`04`	`X`	`ENG`	`@0 Cohort study @5 07`
C03	`04`	`X`	`SPA`	`@0 Estudio cohorte @5 07`
C03	`05`	`X`	`FRE`	`@0 Hospitalisation @5 10`
C03	`05`	`X`	`ENG`	`@0 Hospitalization @5 10`
C03	`05`	`X`	`SPA`	`@0 Hospitalización @5 10`
C03	`06`	`X`	`FRE`	`@0 Canada @2 NG @5 13`
C03	`06`	`X`	`ENG`	`@0 Canada @2 NG @5 13`
C03	`06`	`X`	`SPA`	`@0 Canada @2 NG @5 13`
C03	`07`	`X`	`FRE`	`@0 Epidémiologie @5 17`
C03	`07`	`X`	`ENG`	`@0 Epidemiology @5 17`
C03	`07`	`X`	`SPA`	`@0 Epidemiología @5 17`
C03	`08`	`X`	`FRE`	`@0 Prévalence @5 18`
C03	`08`	`X`	`ENG`	`@0 Prevalence @5 18`
C03	`08`	`X`	`SPA`	`@0 Prevalencia @5 18`
C03	`09`	`X`	`FRE`	`@0 Economie santé @5 19`
C03	`09`	`X`	`ENG`	`@0 Health economy @5 19`
C03	`09`	`X`	`SPA`	`@0 Economía salud @5 19`
C03	`10`	`X`	`FRE`	`@0 Homme @5 20`
C03	`10`	`X`	`ENG`	`@0 Human @5 20`
C03	`10`	`X`	`SPA`	`@0 Hombre @5 20`
C07	`01`	`X`	`FRE`	`@0 Amérique du Nord @2 NG`
C07	`01`	`X`	`ENG`	`@0 North America @2 NG`
C07	`01`	`X`	`SPA`	`@0 America del norte @2 NG`
C07	`02`	`X`	`FRE`	`@0 Amérique @2 NG`
C07	`02`	`X`	`ENG`	`@0 America @2 NG`
C07	`02`	`X`	`SPA`	`@0 America @2 NG`
C07	`03`	`X`	`FRE`	`@0 Trouble neurologique @5 37`
C07	`03`	`X`	`ENG`	`@0 Neurological disorder @5 37`
C07	`03`	`X`	`SPA`	`@0 Trastorno neurológico @5 37`
C07	`04`	`X`	`FRE`	`@0 Système nerveux pathologie @5 38`
C07	`04`	`X`	`ENG`	`@0 Nervous system diseases @5 38`
C07	`04`	`X`	`SPA`	`@0 Sistema nervioso patología @5 38`
C07	`05`	`X`	`FRE`	`@0 Santé publique @5 69`
C07	`05`	`X`	`ENG`	`@0 Public health @5 69`
C07	`05`	`X`	`SPA`	`@0 Salud pública @5 69`
N21				`@1 146`
N82				`@1 PSI`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A80

Links to Exploration step

Pascal:03-0238018

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Burden of parkinsonism: A population-based study</title>
<author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Neurology, Department of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Slaughter, Pamela M" sort="Slaughter, Pamela M" uniqKey="Slaughter P" first="Pamela M." last="Slaughter">Pamela M. Slaughter</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences (ICES)</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Theriault, Marc Erick" sort="Theriault, Marc Erick" uniqKey="Theriault M" first="Marc-Erick" last="Theriault">Marc-Erick Theriault</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences (ICES)</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Deboer, Donald P" sort="Deboer, Donald P" uniqKey="Deboer D" first="Donald P." last="Deboer">Donald P. Deboer</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences (ICES)</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Naylor, C David" sort="Naylor, C David" uniqKey="Naylor C" first="C. David" last="Naylor">C. David Naylor</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences (ICES)</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Dean's Office, Faculty of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0238018</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0238018 INIST</idno>
<idno type="RBID">Pascal:03-0238018</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A80</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000243</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Burden of parkinsonism: A population-based study</title>
<author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Neurology, Department of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Slaughter, Pamela M" sort="Slaughter, Pamela M" uniqKey="Slaughter P" first="Pamela M." last="Slaughter">Pamela M. Slaughter</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences (ICES)</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Theriault, Marc Erick" sort="Theriault, Marc Erick" uniqKey="Theriault M" first="Marc-Erick" last="Theriault">Marc-Erick Theriault</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences (ICES)</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Deboer, Donald P" sort="Deboer, Donald P" uniqKey="Deboer D" first="Donald P." last="Deboer">Donald P. Deboer</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences (ICES)</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Naylor, C David" sort="Naylor, C David" uniqKey="Naylor C" first="C. David" last="Naylor">C. David Naylor</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences (ICES)</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Dean's Office, Faculty of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Canada</term>
<term>Cohort study</term>
<term>Cost analysis</term>
<term>Costs</term>
<term>Epidemiology</term>
<term>Health economy</term>
<term>Hospitalization</term>
<term>Human</term>
<term>Parkinsonism</term>
<term>Prevalence</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinsonisme</term>
<term>Analyse coût</term>
<term>Coût</term>
<term>Etude cohorte</term>
<term>Hospitalisation</term>
<term>Canada</term>
<term>Epidémiologie</term>
<term>Prévalence</term>
<term>Economie santé</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Hospitalisation</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is associated with a significant burden of illness and cost to society, which has been difficult to quantify. Our objective was to use linked administrative databases from the population of Ontario, Canada, to assess the prevalence of parkinsonism, physician- and drug-related costs, and hospital utilization for parkinsonian patients compared with age/sex matched controls. An inception cohort of parkinsonian cases from 1993/ 1994 was age and sex matched (1:2) to controls and followed for 6 years. Patients were identified by the diagnostic code for PD, the use of specific PD drugs, or a combination. The parkinsonian case cohort (15,304) was matched to (30,608) controls that did not have parkinsonism. The age-adjusted prevalence rates were 3.63 for men and for 3.24 women per 1,000 (increased by 5.4% for men and 9.8% for women). Physician costs were 1.4 times more, there were 1.44 times more hospital admissions, admissions were on average 1.19 times longer, and drug costs were 3.0 times more for parkinsonian cases. We conclude that the substantially higher physician and drug costs as well as hospitalization rates compared with controls clearly suggest that parkinsonism is associated with large direct costs to society.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>18</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Burden of parkinsonism: A population-based study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GUTTMAN (Mark)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SLAUGHTER (Pamela M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>THERIAULT (Marc-Erick)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DEBOER (Donald P.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>NAYLOR (C. David)</s1>
</fA11>
<fA14 i1="01"><s1>Division of Neurology, Department of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences (ICES)</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Dean's Office, Faculty of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>313-319</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000109859510100</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>26 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0238018</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Parkinson's disease (PD) is associated with a significant burden of illness and cost to society, which has been difficult to quantify. Our objective was to use linked administrative databases from the population of Ontario, Canada, to assess the prevalence of parkinsonism, physician- and drug-related costs, and hospital utilization for parkinsonian patients compared with age/sex matched controls. An inception cohort of parkinsonian cases from 1993/ 1994 was age and sex matched (1:2) to controls and followed for 6 years. Patients were identified by the diagnostic code for PD, the use of specific PD drugs, or a combination. The parkinsonian case cohort (15,304) was matched to (30,608) controls that did not have parkinsonism. The age-adjusted prevalence rates were 3.63 for men and for 3.24 women per 1,000 (increased by 5.4% for men and 9.8% for women). Physician costs were 1.4 times more, there were 1.44 times more hospital admissions, admissions were on average 1.19 times longer, and drug costs were 3.0 times more for parkinsonian cases. We conclude that the substantially higher physician and drug costs as well as hospitalization rates compared with controls clearly suggest that parkinsonism is associated with large direct costs to society.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17A01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinsonisme</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinsonism</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson síndrome</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Analyse coût</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Cost analysis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Análisis costo</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Coût</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Costs</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Costo</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Etude cohorte</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Cohort study</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Estudio cohorte</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Hospitalisation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Hospitalization</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hospitalización</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Canada</s0>
<s2>NG</s2>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Canada</s0>
<s2>NG</s2>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Canada</s0>
<s2>NG</s2>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Epidémiologie</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Epidemiology</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Epidemiología</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Prévalence</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Prevalence</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Prevalencia</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Economie santé</s0>
<s5>19</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Health economy</s0>
<s5>19</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Economía salud</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Amérique du Nord</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>North America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>America del norte</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Amérique</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Santé publique</s0>
<s5>69</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Public health</s0>
<s5>69</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Salud pública</s0>
<s5>69</s5>
</fC07>
<fN21><s1>146</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000243 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000243 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:03-0238018
   |texte=   Burden of parkinsonism: A population-based study
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Burden of parkinsonism: A population-based study

Burden of parkinsonism: A population-based study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri